Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance.

Viruses - 22 Nov 2022

Richetta Clémence, Tu Nhat Quang, Delelis Olivier

Abstract excerpt

Integrase Strand Transfer Inhibitors (INSTIs) are currently used as the most effective therapy in the treatment of human immunodeficiency virus (HIV) infections. Raltegravir (RAL) and Elvitegravir (EVG), the first generation of INSTIs used successfully in clinical treatment, are susceptible to the emergence of viral resistance and have a high rate of cross-resistance. To counteract these resistant mutants,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to Heterocyclic Compounds, 3-Ring
Share to HIV Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Integrase

Share to HIV Integrase Inhibitors

Share to Integrases

Share to Mutation

Share to Raltegravir Potassium

Source

Open in PubMed Open full text

Identifiers

PMID: 36560595
DOI: 10.3390/v14122591
PMCID: PMC9785060

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance.PMID 36560595Read ↗

HIV drug resistance against strand transfer integrase inhibitors.Semantic proximity Read ↗

Will drug resistance against dolutegravir in initial therapy ever occur?Semantic proximity Read ↗

Dolutegravir resistance mutations: lessons from monotherapy studies.Semantic proximity Read ↗

Integrase strand transfer inhibitors in the management of HIV-positive individualsSemantic proximity Read ↗

Emerging patterns and implications of HIV-1 integrase inhibitor resistanceSemantic proximity Read ↗

Evolution of HIV integrase resistance mutations.Semantic proximity Read ↗

Resistance to Integrase InhibitorsSemantic proximity Read ↗

Integrase Strand Transfer Inhibitors in HIV TherapySemantic proximity Read ↗

Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive PatientsSemantic proximity Read ↗

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV PersistenceSemantic proximity Read ↗

HIV-1 Integrase Inhibitor Resistance and Its Clinical ImplicationsSemantic proximity Read ↗

Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimensSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.